Mirum Pharmaceuticals Reports Strong 2025 Results, Issues Robust 2026 Sales Guidance, and Highlights Key Pipeline Catalysts
Summary
Mirum Pharmaceuticals reported strong full-year 2025 financial results, including significant product sales growth, and provided optimistic 2026 sales guidance alongside a robust pipeline update with multiple key data readouts expected.
Key Events
-
Strong 2025 Financial Performance
Reported total net product sales of $521.3 million for the full year 2025, a substantial increase from $336.4 million in 2024. LIVMARLI sales grew 69% year-over-year to $360.0 million.
-
Robust 2026 Sales Guidance
Issued 2026 global net product sales guidance of $630 million to $650 million, indicating continued strong commercial growth.
-
Key Pipeline Catalysts Expected in 2026
Anticipates multiple late-stage clinical trial readouts, including Volixibat VISTAS study (PSC) topline data in Q2 2026, LIVMARLI EXPAND study topline data in Q4 2026, and Brelovitug AZURE-1 and AZURE-4 studies (HDV) topline data in H2 2026.
-
Improved Financial Position
Reduced net loss to $23.363 million for 2025 from $87.942 million in 2024, and increased unrestricted cash, cash equivalents, and investments to $391.4 million as of December 31, 2025.
Analysis
Mirum Pharmaceuticals delivered strong financial results for 2025, significantly increasing net product sales and reducing its net loss. The company's 2026 sales guidance of $630 million to $650 million indicates continued robust growth, building on the momentum from its approved products like LIVMARLI. Furthermore, the detailed pipeline update, with multiple late-stage clinical trial readouts expected throughout 2026, provides significant catalysts for future value creation in a catalyst-rich period for the company. The improved cash position also strengthens its financial flexibility.
At the time of this filing, MIRM was trading at $108.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $36.88 to $109.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.